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Transplant-associated coronary artery disease (TxCAD), or
coronary vasculopathy, is the leading cause of death after the
first year of transplantation and, once diagnosed, is associ-
ated with a mortality rate of40% at two years (1). Though
coronary vasculopathy is widely believed to represent some
form of chronic humoral and cellular rejection, some non-
immune risk factors such as older donor age, ischemia time,
dyslipidemia, preexisting donor coronary artery disease
(CAD) and post-transplantation cytomegalovirus infection
have also been identified (2,3). These risk factors suggest
that both immune and nonimmune causes probably interact
to lead to coronary vasculopathy, although the precise
mechanisms involved remain poorly understood.
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In this issue of the Journal, Yamani et al. (4) performed a
prospective study involving 140 cardiac allograft transplant
recipients and correlated the degree of post-transplant
ischemia and interstitial fibrosis with the development of
coronary vasculopathy progression, acute cellular rejection
and long-term outcome. Coronary vasculopathy progression
was determined by comparing baseline intravascular ultra-
sound (IVUS) measurements at one month post-transplant
to end point measurements taken at one year post-
transplant. Serial endomyocardial biopsies were evaluated
for evidence of ischemia, fibrosis and vascular rejection, and
patients were divided into four groups (ischemia, fibrosis,
vascular and nonischemic) based on histologic and immu-
nofluorescence criteria. To determine how each of these
four biopsy categories were correlated with standard cellular
rejection, a cellular rejection score was calculated for each
patient based on the average International Society for Heart
and Lung Transplantation (ISHLT) grade of rejection (5)
during the first year post-transplantation. Thus, for every
patient, in addition to routine assessments of cellular/
humoral rejection episodes, the investigators determined
whether patients developed biopsy evidence of peritrans-
plant ischemia and which patients progressed to interstitial
fibrosis and vascular rejection.
Of the 140 patients studied, a group of 32 (23%) patients
did not demonstrate evidence of either peritransplant isch-
emia, fibrosis or vascular rejection. This group had the least
coronary vasculopathy progression by IVUS, and the lowest
proportion of patients developing significant late post-
TxCAD. Interestingly, this “nonischemic” group did not
have the lowest average cellular rejection scores, supporting
the view that the number of acute rejection episodes does
not by itself predict the development of post-transplant
coronary vasculopathy. All the remaining 108 patients were
found to have some evidence of either ischemia, fibrosis or
vascular rejection—24 (17%) developed peritransplant isch-
emia alone while the remaining 84 patients developed either
peritransplant ischemia followed by interstitial fibrosis (n 
62) or vascular rejection (n  22). Of interest was the
finding that 18 of these 22 patients (82%) in the vascular
rejection group also had peritransplant ischemia followed by
interstitial fibrosis. Therefore, of the 140 patients studied,
80 (57%) developed peritransplant ischemia followed by
interstitial fibrosis.
The important finding in this study was that the 62
patients in the fibrosis group had the fewest average number
of cellular rejection episodes and the lowest incidence of
donor-specific human leukocyte antigen (HLA) sensitiza-
tion, yet had the most severe coronary vasculopathy, the
highest proportion of late TxCAD and the poorest5-year
event-free survival rates. Also, patients in the vascular
(humoral) rejection group who had the highest average
episodes of cellular rejection only rarely (6%) progressed
to clinically significant late TxCAD. Thus, the investi-
gators make a strong case for the presence of nonimmune
mechanisms in mediating the pathogenesis of allograft
vasculopathy.
Nonimmune mechanisms of coronary vascular injury or
hidden immune mechanisms? Does a low incidence of
acute cellular rejection and donor-specific HLA sensitiza-
tion indicate that “nonimmune mechanisms” are mediating
the coronary vascular injury? If the researchers (4) imply that
classical acquired (antigen specific) humoral and cellular
immune mechanisms are not associated with the develop-
ment of early coronary vasculopathy and late TxCAD, then
data from this study seem to lend support for this view.
Patients within the fibrosis group had the lowest average
episodes of cellular rejection, the lowest incidence of donor-
specific HLA sensitization, yet experienced the highest
incidence of coronary vasculopathy. However, we know that
there are natural (nonantigen specific) innate immune
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the †Division of Cardiology, Department of Medicine, San Francisco
Veterans Affairs Medical Center, San Francisco, California, and the ‡Department of
Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta,
Georgia.
Journal of the American College of Cardiology Vol. 39, No. 6, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)01705-9
mechanisms consisting of natural killer (NK) and macro-
phage cell lineages that have been implied to play a role in
inducing coronary vasculopathy in murine organ transplant
models (6). Specifically, a high frequency of organ trans-
plant recipient mice incapable of mounting classical ac-
quired immune responses (RAG-/- and SCID mice) have
been shown to develop proximal coronary lesions, which
were markedly reduced if recipients were treated with
antibodies specifically directed at the NK cell lineages (6). A
role for such potential innate nonantigen-specific immune-
mediated mechanisms has not been appreciated so far; thus,
such mechanisms are not included in the standard ISHLT
cellular rejection scoring system (5).
Can immune mechanisms be involved in coronary vascu-
lopathy in the absence of histologic evidence of acute
cellular or humoral rejection? The answer to this question is
yes. First, we know that in the ISHLT grading system for
heart transplant biopsy specimens (5), the milder forms of
rejection (grades 0 to 2) denote the presence of interstitial
immune cell infiltration that do not usually require bolus
immunosuppressive therapy. Thus, the low number of acute
rejection episodes (ISHLT grade 3) in patients with
post-transplant fibrosis is not synonymous with lack of
immune cell trafficking within the myocardium. Second,
donor alloantigens can be shed by the graft, picked up by
roving macrophages/dendritic cells and taken to local lymph
nodes, leading to alloimmune responses. This is termed the
“indirect pathway,” whereby soluble donor major histocom-
patibility complex (MHC) antigens are processed into
peptides and these donor MHC peptides are presented by
recipient MHC molecules to recipient effector T cells.
Activation of recipient T cells could lead to the generation
of interferon-gamma (IFN-) systemically at levels that
could lead to coronary vasculopathy. The fact that indirect
pathways have been shown to be involved in coronary
vasculopathy (7) and that infusion of IFN- alone in the
absence of leukocytes can induce arteriosclerosis (8) sup-
ports this view. Thus, one must be cautious in interpreting
the data in the Yamani et al. (4) study, which suggest that
the development of coronary vasculopathy in the absence of
a high average cellular rejection score provides evidence for
the role of nonimmune involvement in the form of ischemia
and fibrosis.
Conversely, can coronary vasculopathy develop without
histocompatibility mismatches and cellular rejection? Per-
haps the strongest evidence that some form of innate,
acquired and/or both immune mechanisms must be in-
volved in the development of coronary vasculopathy has
come from the fact that isogenic murine and rat cardiac
transplants develop little detectable evidence of coronary
vasculopathy. This observation has suggested that incom-
patibility (be it [MHC] class I or class II or non-MHC
incompatibility) must contribute in some way to coronary
vasculopathy. However, a recent study has suggested that
under certain conditions, nonimmune mechanisms may be
the major if not sole mediator of post-transplant vasculopa-
thy. Using a genetically similar rat cardiac isograft model,
Cantin et al. (9) have shown that significant coronary
vasculopathy can develop without histocompatibility mis-
matches or cellular rejection.
Limitations. The limitations of the Yamani et al. (4) study
are important. The 140 patients who completed the IVUS
study at one year represented only one-third of the total of
422 patients who underwent heart transplantation at the
Cleveland Clinic Foundation from 1992 to 1997. The basis
by which patients would undergo serial IVUS studies may
have led to unanticipated selection bias. In addition, all
patients in the study were classified into nonischemic,
ischemia, fibrosis and vascular rejection groups. The defini-
tion of the important fibrosis group was “patients who
developed peritransplant ischemia followed by interstitial
fibrosis in the absence of vascular rejection.” Unfortunately,
no specific criteria were provided on precisely how the
histologic diagnosis of post-transplant fibrosis was made.
For example, is the presence of interstitial fibrosis on one
biopsy sufficient or must multiple biopsies be affected? The
bias associated with biopsy sampling is also an important
issue in this regard. Thus, investigators in other centers will
have to create their own criteria to try to reproduce these
important findings.
Another major issue concerning the findings by Yamani
et al. (4) is a lack of clarity as to the potential nonimmune-
mediated mechanisms that perpetuate fibrosis for long
periods of time following ischemia in such patients. Thus,
fibrosis/smooth muscle cell proliferation and remodeling
must require a continuous source of a number of growth
factors/cytokines. What is the source of such growth factors
and cytokines that are localized to the transplanted heart? If
indeed ischemic events are initiators of this process, why is
such a process perpetuated and why is such a process not
regulated? Future studies are required to more definitively
ascribe a role for such ischemic nonimmune-mediated
events to induce post-TxCAD.
In addition, patients were evaluated by IVUS and serial
endomyocardial biopsies for only one year post-transplant,
and during that year both graft failure and clinically appar-
ent coronary vasculopathy were very rare. It was over an
average of 67 months of follow-up that the fibrosis group
experienced poor long-term outcome and a higher propor-
tion (32%) of moderate–severe vasculopathy. Yet, one year
after transplantation, no pathology data were provided from
autopsy and retransplantation specimens. Did the group
with interstitial fibrosis in the first year after transplant
continue to have lower cellular rejection scores past their
first post-transplant year? Did the patients with the worst
outcomes, namely graft failure and death, have evidence of
advanced coronary vasculopathy without histologic evidence
of interstitial and vascular inflammation? It is also important
to note that clinical data that might have confounded the
effect between the presence of fibrosis and coronary vascu-
lopathy, such as lipid levels, were not provided.
In addition, two other points are worth mentioning. One
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is the specificity of the finding of interstitial fibrosis. It is
difficult to understand how patients in the fibrosis group
develop the most severe late TxCAD, whereas patients in
the vascular rejection group, who also have fibrosis, only
rarely develop coronary vasculopathy. The data in the study
(4) suggest that when fibrosis is accompanied by vascular
rejection it is not predictive of coronary vasculopathy pro-
gression.
Second, though the investigators (4) used immunofluo-
rescence staining for IgM and complement to identify
vascular rejection, they failed to look for other recognized
markers associated with immune-mediated vascular injury.
The expression of MHC class I and class II antigens and
intercellular adhesion molecule (ICAM)-1 on arterial/
arteriolar endothelium in transplant allografts during the
first three months after transplant has been shown to predict
the development of late TxCAD and graft failure (10). The
finding of aberrant MHC and induced ICAM-1 expression
on arterial endothelium would represent a more sensitive
and specific marker of immune-mediated targeting than the
average cellular rejection score.
Whatever the case, the study by Yamani et al. (4)
demonstrates that early post-transplant fibrosis was associ-
ated with increased risk of coronary vasculopathy and poor
overall long-term outcome. Is it possible that the simple
histologic finding of interstitial fibrosis is a marker for a
predisposition to develop late TxCAD? We believe that this
may be possible. The presence of interstitial fibrosis on early
post-transplant endomyocardial biopsies is secondary to
remodeling due to postischemic reperfusion injury. Patients
with a genetic predisposition to cardiac interstitial prolifer-
ation may be predisposed to intravascular proliferation in
response to a myriad of stimuli, both immune and nonim-
mune mediated. The possibility that genetic predisposition
may modulate immune responses following post-ischemic
reperfusion is supported by recent studies documenting that
specific interleukin-6 (IL-6) promoter polymorphisms in-
fluence the amount of IL-6 that individual patients produce
after coronary artery bypass graft surgery (11). In the
post-transplant setting, it is certainly possible that genetic
influences on levels of growth factor(s) that may be impli-
cated in both the development of interstitial fibrosis and
coronary vasculopathy (i.e., fibroblast growth factor) are
involved. If this is the case, then patients with a long-term
risk for developing coronary vasculopathy may be simply
identified by their predisposition to develop interstitial
fibrosis in the year following cardiac transplantation.
Conclusions. Finally, though the data presented by Ya-
mani et al. (4) are clearly interesting and provide impetus for
continued studies on the mechanisms by which nonclassical
immune-mediated mechanisms contribute to post-TxCAD,
it is important to be wary of the terminology we utilize until
such mechanisms are more fully defined. A role for the
contribution of NK cells and indirect pathways of allorecog-
nition in concert with the precise mechanisms that perpet-
uate long-term fibrosis and coronary vasculopathy needs to
be a focus of future studies.
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